NLS Pharmaceutics (NASDAQ:NCEL) Director Purchases $149,998.75 in Stock

NLS Pharmaceutics Ltd. (NASDAQ:NCEL) Director Michel Revel acquired 54,545 shares of the stock in a transaction dated Monday, April 27th. The stock was acquired at an average price of $2.75 per share, for a total transaction of $149,998.75. Following the purchase, the director directly owned 957,530 shares in the company, valued at approximately $2,633,207.50. This trade represents a 6.04% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink.

NLS Pharmaceutics Trading Down 12.7%

Shares of NASDAQ:NCEL opened at $3.85 on Friday. The firm’s 50 day moving average price is $2.76 and its 200-day moving average price is $4.04. NLS Pharmaceutics Ltd. has a twelve month low of $1.83 and a twelve month high of $30.80.

NLS Pharmaceutics Company Profile

NLS Pharmaceutics (NASDAQ: NCEL) is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, with additional operations in the United States. The company focuses on the development of small-molecule therapies designed to address disorders of the circadian rhythm and sleep-wake cycle. It leverages proprietary controlled-release and receptor-targeting approaches to optimize drug exposure over a 24-hour period.

The core of NLS Pharmaceutics’ pipeline consists of novel melatonin receptor agonists aimed at treating rare and orphan sleep disorders such as non-24-hour sleep-wake disorder and idiopathic hypersomnia.